Acrivon Therapeutics Long Term Debt

Acrivon Therapeutics (ACRV) currently reports a long-term debt of $980K as of June 2026. That compares with $2.1M in the prior-year period — down 53.7% year over year. Use the charts on this page to explore Acrivon Therapeutics's long-term debt history and peer comparisons.

Acrivon Therapeutics's long-term debt decreased from $2.1M to $980K — a 53.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acrivon Therapeutics reported $980K in long-term debt as of June 2026. That compares with $2.1M in the prior-year period — down 53.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $980K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acrivon Therapeutics, and consider following ACRV for alerts when major investors trade the stock.